BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
2 Tunis AS, Mcinnes MDF, Hanna R, Esmail K. Association of Study Quality with Completeness of Reporting: Have Completeness of Reporting and Quality of Systematic Reviews and Meta-Analyses in Major Radiology Journals Changed Since Publication of the PRISMA Statement? Radiology 2013;269:413-26. [DOI: 10.1148/radiol.13130273] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 12.6] [Reference Citation Analysis]
3 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
4 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
5 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
6 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
7 Chow DS, Bahrami S, Raman SS, Rotchel S, Sayre JW, Busuttil RW, Lu DS. Risk of nephrogenic systemic fibrosis in liver transplantation patients. AJR Am J Roentgenol. 2011;197:658-662. [PMID: 21862808 DOI: 10.2214/ajr.10.5976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6:553-558. [PMID: 26253982 DOI: 10.1007/s13244-015-0420-2] [Cited by in Crossref: 111] [Cited by in F6Publishing: 86] [Article Influence: 18.5] [Reference Citation Analysis]
9 Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566. [PMID: 21623212 DOI: 10.1097/rli.0b013e31821a218a] [Cited by in Crossref: 69] [Cited by in F6Publishing: 16] [Article Influence: 6.9] [Reference Citation Analysis]
10 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Lunyera J, Mohottige D, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review. Ann Intern Med 2020;173:110-9. [PMID: 32568573 DOI: 10.7326/M20-0299] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
13 Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR. An evaluation of the sensitivity of MRI at detecting hepatocellular carcinoma in cirrhotic patients utilizing an explant reference standard. Clinical Imaging 2014;38:693-7. [DOI: 10.1016/j.clinimag.2014.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
15 Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
16 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
17 van der Pol CB, McInnes MD, Petrcich W, Tunis AS, Hanna R. Is quality and completeness of reporting of systematic reviews and meta-analyses published in high impact radiology journals associated with citation rates? PLoS One 2015;10:e0119892. [PMID: 25775455 DOI: 10.1371/journal.pone.0119892] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
18 Kapadia A, Mehrabian H, Conklin J, Symons SP, Maralani PJ, Stanisz GJ, Sahgal A, Soliman H, Heyn CC. Temporal evolution of perfusion parameters in brain metastases treated with stereotactic radiosurgery: comparison of intravoxel incoherent motion and dynamic contrast enhanced MRI. J Neurooncol 2017;135:119-27. [PMID: 28669014 DOI: 10.1007/s11060-017-2556-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
20 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]